Inducing cell cycle arrest and apoptosis by dimercaptosuccinic acid modified Fe₃O₄ magnetic nanoparticles combined with nontoxic concentration of bortezomib and gambogic acid in RPMI-8226 cells

References

• ChangWJGlebovOBergsagelPLKuehlWMGenetic events in the pathogenesis of multiple myelomaBest Pract Res Clin Haematol20072057159618070707
   PubMed Web of Science ®Google Scholar
• KyleRARajkumarSVMultiple myelomaBlood20081112962297218332230
   PubMed Web of Science ®Google Scholar
• PalumboAAndersonKMultiple myelomaN Engl J Med20113641046106021410373
   PubMed Web of Science ®Google Scholar
• LaubachJPMitsiadesCSMahindraANovel therapies in the treatment of multiple myelomaJ Natl Compr Canc Netw2009794796019878638
   PubMed Web of Science ®Google Scholar
• MaMHYangHHParkerKThe proteasome inhibitor PS-341 markedly enhances sensitivity of multiple myeloma tumor cells to chemotherapeutic agentsClin Cancer Res200391136114412631619
   PubMed Web of Science ®Google Scholar
• HideshimaTRichardsonPChauhanDThe proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cellsCancer Res2001613071307611306489
   PubMed Web of Science ®Google Scholar
• SiegelRNaishadhamDJemalACancer statisticsCA Cancer J Clin201262102922237781
   PubMed Web of Science ®Google Scholar
• Van BesienKCurrent status of allogeneic transplantation for aggressive non-Hodgkin lymphomaCurr Opin Oncol20112368169121946246
   PubMed Web of Science ®Google Scholar
• FoxERazzoukBIWidemannBCPhase 1 trial and pharmacokinetic study of arsenic trioxide in children and adolescents with refractory or relapsed acute leukemia, including acute promyelocytic leukemia or lymphomaBlood200811156657317959855
   PubMed Web of Science ®Google Scholar
• HideshimaTNeriPTassonePMLN120B, a novel IkappaB kinase beta inhibitor, blocks multiple myeloma cell growth in vitro and in vivoClin Cancer Res2006125887599417020997
   PubMed Web of Science ®Google Scholar
• TakamatsuYSunamiKHataHThe Kyushu Hematology Organization for Treatment Study GroupA phase I study of bortezomib in combination with doxorubicin and intermediate-dose dexamethasone (iPAD therapy) for relapsed or refractory multiple myelomaInt J Hematol20109250350920824401
   PubMed Web of Science ®Google Scholar
• TakamatsuYSunamiKMutaTThe Kyushu Hematology Organization for Treatment Study GroupBortezomib, doxorubicin and intermediate-dose dexamethasone (iPAD) therapy for relapsed or refractory multiple myeloma: a multicenter phase 2 studyInt J Hematol20139817918523832805
   PubMed Web of Science ®Google Scholar
• YangLJChenYNew targets for the antitumor activity of gambogic acid in hematologic malignanciesActa Pharmacol Sin20133419119823274413
   PubMed Web of Science ®Google Scholar
• LiXLiuSHuangHGambogic acid is a tissue-specific proteasome inhibitor in vitro and in vivoCell Rep2013321122223260670
   PubMed Web of Science ®Google Scholar
• WangYXiangWWangMMethyl jasmonate sensitizes human bladder cancer cells to gambogic acid-induced apoptosis through down-regulation of EZH2 expression by miR-101Br J Pharmacol201417161863524490857
   PubMed Web of Science ®Google Scholar
• DuanDZhangBYaoJGambogic acid induces apoptosis in hepatocellular carcinoma SMMC-7721 cells by targeting cytosolic thioredoxin reductaseFree Radic Biol Med201469152524407164
   PubMed Web of Science ®Google Scholar
• KoppoluBBhavsarZWadajkarASTemperature-sensitive poly-mercoated magnetic nanoparticles as a potential drug delivery system for targeted therapy of thyroid cancerJ Biomed Nanotechnol2012898399023030006
   PubMed Web of Science ®Google Scholar
• ChananaMMaoZWWangDYUsing polymers to make up magnetic nanoparticles for biomedicineJ Biomed Naonotechnol20095652668
   PubMed Web of Science ®Google Scholar
• MbehDAFrançaRMerhiYIn vitro biocompatibility assessment of functionalized magnetite nanoparticles: biological and cytotoxicological effectsJ Biomed Mater Res201210016371646
   Google Scholar
• QiaoRRZengJFJiaQJMagnetic iron oxide nanoparticle an important cornerstone of MR molecular imaging of tumorsActa Phys Chim Sin2012289931001
   Web of Science ®Google Scholar
• ZhangXJiangLZhangCA silicon dioxide modified magnetic nanoparticles labeled flow strip for HBs antigenJ Biomed Nanotechnol2011777678122416576
   PubMed Web of Science ®Google Scholar
• MaCLiCHeNPreparation and characterization of monodisperse core–shell Fe3O4@SiO2 Microspheres and its application for magnetic separation of nucleic acids from E. coli BL21J Biomed Nanotechnol201281000100523030008
   PubMed Web of Science ®Google Scholar
• OliveiraRRFerreiraFSCintraERBranquinhoLCBakuzisAFLimaEMMagnetic nanoparticles and rapamycin encapsulated into polymeric nanocarriersJ Biomed Nanotechnol2012819320122515070
   PubMed Web of Science ®Google Scholar
• SinghRNalwaHSMedical applications of nanoparticles in biological imaging, cell labeling, antimicrobial agents and anticancer nanodrugsJ Biomed Nanotechnol2011748950321870454
   PubMed Web of Science ®Google Scholar
• CaiXCaiXWangCAntitumor efficacy of DMSA modified Fe3O4 magnetic nanoparticles combined with arsenic trioxide and adriamycin in Raji CellsJ Biomed Nanotechnol20141025126124738333
   PubMed Web of Science ®Google Scholar
• ChenZPZhangYXuKXuRZLiuJWGuNStability of hydrophilic magnetic nanoparticles under biologically relevant conditionsJ Nanosci Nanotechnol200886260626519205192
   PubMed Web of Science ®Google Scholar
• ChenZPZhangYXiaJGPreparation and characterization of water-soluble monodisperse magnetic iron nanoparticles via surface double-exchange with DMSAColloid Surface2008316210216
   Web of Science ®Google Scholar
• JiangZChenBAXiaGHThe reversal effect of magnetic Fe3O4 nanoparticles loaded with cisplatin on SKOV3/DDP ovarian carcinoma cellsInt J Nanomed20094107114
   PubMed Web of Science ®Google Scholar
• ZhaoLGuoQLYouQDWuZQGuHYGambogic acid induces apoptosis and regulates expressions of Bax and Bcl-2 protein in human gastric carcinoma MGC-803 cellsBiol Pharm Bull200427998100315256729
   PubMed Web of Science ®Google Scholar
• ChengJWuWWChenBAEffect of magnetic nanoparticles of Fe3O4 and 5-bromotetrandrine on reversal of multidrug resistance in K562/A02 leukemic cellsInt J Nanomed20094209216
   PubMed Web of Science ®Google Scholar
• LowryOHRosebroughNJFarrALRandallRJProtein measurement with the Folin phenol reagentsJ Biol Chem195119326527514907713
   PubMed Web of Science ®Google Scholar
• WangFZhangWGuoLGambogic acid suppresses hypoxia-induced hypoxia-inducible factor-1/vascular endothelial growth factor expression via inhibiting phosphatidylinositol 3-kinase/Akt/mammalian target protein of rapamycin pathway in multiple myeloma cellsCancer Sci201410581063107024890366
   PubMed Web of Science ®Google Scholar
• ChenBLiangYWuWSynergistic effect of magnetic nanoparticles of Fe3O4 with gambogic acid on apoptosis of K562 leukemia cellsJ Biomed Nanotechnol20094251259
   Google Scholar
• WangXDengRLuYGambogic acid as a non-competitive inhibitor of ATP-binding cassette transporter B1 reverses the multidrug resistance of human epithelial cancers by promoting ATP-binding cassette transporter B1 protein degradationBasic Clin Pharmacol Toxicol2013112253322759348
   PubMed Web of Science ®Google Scholar
• QiQYouQGuHStudies on the toxicity of gambogic acid in ratsJ Ethnopharmacol200811743343818384990
   PubMed Web of Science ®Google Scholar
• ValoisCRBrazJMNunesESThe effect of DMSA-functionalized magnetic nanoparticles on transendothelial migration of monocytes in the murine lung via aβ2 integrin-dependent pathwayBiomaterials20103136637419822361
   PubMed Web of Science ®Google Scholar
• BarryMABehnkeCAEastmanAActivation of programmed cell death (apoptosis) by cisplatin, other anticancer drugs, toxins and hyperthermiaBiochem Pharmacol199040235323622244936
   PubMed Web of Science ®Google Scholar
• LuHYuanGXHeQHRapid analysis of anthracycline antibiotics doxorubicin and daunorubicin by microchip capillary electrophoresisMicrochem J200992170175
   Web of Science ®Google Scholar
• HarveyRDLonialSPI3 kinase/AKT pathway as a therapeutic target in multiple myelomaFuture Oncol2007363964718041916
   PubMedGoogle Scholar
• IkedaHHideshimaTFulcinitiMPI3K/p110{delta} is a novel therapeutic target in multiple myelomaBlood20101161460146820505158
   PubMed Web of Science ®Google Scholar
• HsuJShiYKrajewskiSThe AKT kinase is activated in multiple myeloma tumor cellsBlood2001982853285511675360
   PubMed Web of Science ®Google Scholar
• MaoXCaoBWoodTEA small-molecule inhibitor of D-cyclin transactivation displays preclinical efficacy in myeloma and leukemia via phosphoinositide 3-kinase pathwayBlood20111171986199721135258
   PubMed Web of Science ®Google Scholar
• HennessyBTSmithDLRamPTLuYMillsGBExploiting the PI3K/AKT pathway for cancer drug discoveryNat Rev Drug Discov20054988100416341064
   PubMed Web of Science ®Google Scholar
• TofaniSBaroneDBerardelliMStatic and ELF magnetic fields enhance the in vivo antitumor efficacy of cisplatin against Lewis lung carcinoma, but not of cyclophosphamide against B16 melanotic melanomaPharmacol Res200348839012770519
   PubMed Web of Science ®Google Scholar
• JajteJGrzegorczykJZmyslonyMRajkowskaEEffect of 7mT static magnetic field and iron ions on rat lymphocytes: apoptosis, necrosis and free radical processesBioelectrochemistry20025710711112160605
   PubMed Web of Science ®Google Scholar
• LiuNHuangHXuLThe combination of proteasome inhibitors bortezomib and gambogic acid triggers synergistic cytotoxicity in vitro but not in vivoToxicology Let2014224333340
   PubMed Web of Science ®Google Scholar